Literature DB >> 16815078

Candida albicans biofilm development, modeling a host-pathogen interaction.

Jeniel Nett1, David Andes.   

Abstract

Medical device-associated infections involve the attachment of cells to a surface, production of an extracellular matrix and development of a mature biofilm. Many Candida albicans disease states involve biofilm growth. These infections have great impact on public health because organisms in biofilms exhibit dramatically reduced susceptibility to antifungal therapy. Progression to a mature biofilm is dependent on cell adhesion, extracellular matrix production and the yeast-to-hyphae transition. Numerous in vitro biofilm model systems have been successfully used to examine biofilm architecture, development, cell phenotypes and drug resistance. Although these studies have included a number of experimental variables to mimic infections in patients, it is difficult to accurately account for the multitude of host and infection-site variables that are probably important in humans. Recent studies have begun to explore C. albicans biofilms using animal biofilm infection models in order to more completely reflect the complexity of this host-fungal interaction.

Entities:  

Mesh:

Year:  2006        PMID: 16815078     DOI: 10.1016/j.mib.2006.06.007

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  74 in total

Review 1.  Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework.

Authors:  Mary Ann Jabra-Rizk; Eric F Kong; Christina Tsui; M Hong Nguyen; Cornelius J Clancy; Paul L Fidel; Mairi Noverr
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

2.  Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors:  Peter M Silver; Brian G Oliver; Theodore C White
Journal:  Med Mycol       Date:  2008-05       Impact factor: 4.076

3.  A 96 well microtiter plate-based method for monitoring formation and antifungal susceptibility testing of Candida albicans biofilms.

Authors:  Christopher G Pierce; Priya Uppuluri; Sushma Tummala; Jose L Lopez-Ribot
Journal:  J Vis Exp       Date:  2010-10-21       Impact factor: 1.355

Review 4.  Candida albicans cell wall proteins.

Authors:  W LaJean Chaffin
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

Review 5.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

6.  Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

Authors:  M Guembe; J Guinea; L J Marcos-Zambrano; A Fernández-Cruz; T Peláez; P Muñoz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

Review 7.  Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.

Authors:  Jinhui Cui; Biao Ren; Yaojun Tong; Huanqin Dai; Lixin Zhang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

8.  The role of Mss11 in Candida albicans biofilm formation.

Authors:  Pei-Wen Tsai; Yu-Ting Chen; Cheng-Yao Yang; Hsueh-Fen Chen; Te-Sheng Tan; Tzung-Wei Lin; Wen-Ping Hsieh; Chung-Yu Lan
Journal:  Mol Genet Genomics       Date:  2014-04-22       Impact factor: 3.291

Review 9.  Pathogenesis of mucosal biofilm infections: challenges and progress.

Authors:  Anna Dongari-Bagtzoglou
Journal:  Expert Rev Anti Infect Ther       Date:  2008-04       Impact factor: 5.091

10.  Candida albicans and non-C. albicans Candida species: comparison of biofilm production and metabolic activity in biofilms, and putative virulence properties of isolates from hospital environments and infections.

Authors:  A V Ferreira; C G Prado; R R Carvalho; K S T Dias; A L T Dias
Journal:  Mycopathologia       Date:  2013-03-27       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.